From our previous study, we identified SIK3 as a novel ovarian TAA that is highly and preferentially expressed in ovarian cancer but not in benign gynecologic diseases, i.e., adenomyosis or endometriosis, with elevated CA125 levels. Here, SIK3 is linked to endometriosis.